Search clinical trials for: 5 mg empagliflozin

Total 17332 results

Pfizer

Withdrawn

A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

Dementia | Alzheimer's Disease | Dimebon | Investigational Drug
Bayer

Completed

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Heart Failure

Belgium, France, Switzerland, United States, Spain, Greece, Japan, Singapore, Austria, Germany, Korea, Republic of, Poland, Denmark, Israel, Netherlands, Taiwan, Bulgaria, Canada, Sweden, Czechia, Australia, Italy, Hungary, United Kingdom
Conatus Pharmaceuticals Inc.

Completed

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)

Liver Diseases | Fibrosis | Non-alcoholic Steatohepatitis

United States, Spain, Germany
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Healthy Subjects

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Healthy Subjects

Canada
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
Bayer
Merck Sharp & Dohme LLC; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF (VITALITY-HFpEF)

Chronic Heart Failure With Preserved Ejection Fraction

Spain, United States, Belgium, Singapore, Taiwan, Canada, Japan, Italy, Austria, Bulgaria, Germany, Greece, Israel, Poland, Portugal, Hungary, Russian Federation, Argentina, Colombia, Malaysia, South Africa
Omar Tarek Elfarargi

Not yet recruiting

Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease (SGLT2i VS ACEi)

Diabetic Nephropathy Type 2
University of Sao Paulo General Hospital

Recruiting

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) (SAFE-PCI)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury

Brazil
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
General and Teaching Hospital Celje

Completed

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients (ENDIS)

Diabetes Mellitus, Type 1 | Biomarkers | Endothelial Dysfunction | Arterial Stiffness | FMD | Incretins | Endothelial Progenitor Cells | SGLT 2 Inhibitors | Glucose Excursions | FPF

Slovenia
Chungbuk National University Hospital

Active, not recruiting

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy (LUCID)

Diabetes Mellitus, Type 2
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
Pfizer

Terminated

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Healthy

Singapore
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Ferring Pharmaceuticals

Terminated

Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Sweden, Canada, Hungary, United States, Brazil, South Africa, Czech Republic, Germany, Mexico, Poland, Slovakia, United Kingdom
Regional Hospital Holstebro

Completed

The Effects of Isotonic and Hypertonic Saline Infusion on Renal Biomarkers in Healthy Young Subjects (NARA)

Nephropathy

Denmark
Damanhour University
Tanta University

Recruiting

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Coronary Artery Disease | Type 2 Diabetes

Egypt
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Ketones, SGLT2, HFrEF

Heart Failure With Reduced Ejection Fraction | Type2diabetes

United States
University of Catanzaro

Completed

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) (FIORE)

Type 2 Diabetes | Cardiovascular Risk Factor

Italy
EMS

Withdrawn

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Type2 Diabetes Mellitus
Oslo University Hospital
Vestre Viken Hospital Trust; University of Oslo; The Research Council of Norway; University Hospital, Akershus and other collaborators

Recruiting

Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose (DIASA3)

Glucose Metabolism Disorders | Impaired Glucose Tolerance | Insulin Sensitivity

Norway
Miulli General Hospital

Not yet recruiting

Empagliflozin and Atrial Fibrillation Treatment (EMPA-AF)

Heart Failure | Obesity | Diabetes Mellitus | Atrial Fibrillation

Italy
McGill University Health Centre/Research Institute...

Recruiting

Empagliflozin in Acute Heart Failure (DRIP-AHF-1)

Chronic Kidney Diseases | Acute Heart Failure

Canada
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
GlaxoSmithKline

Completed

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

Gastroparesis

United States, Australia, Belgium, United Kingdom, Canada, Sweden
Rehab Werida
University of Alexandria

Recruiting

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Type 2 Diabetes | Nonalcoholic Fatty Liver Disease

Egypt
Teva Pharmaceuticals USA

Completed

Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed

Healthy

Canada
Jinnah Postgraduate Medical Centre

Not yet recruiting

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Non-Alcoholic Fatty Liver Disease | Type2diabetes

Pakistan
Cytokinetics
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.

Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM) (SEQUOIA-HCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)

United States, France, Spain, Portugal, Germany, China, United Kingdom, Israel, Netherlands, Denmark, Czechia, Hungary, Italy, Poland
Rezolute

Recruiting

RZ358 Treatment for Congenital Hyperinsulinism (sunRIZE)

Congenital Hyperinsulinism

Bulgaria, Canada, Denmark, France, Georgia, Germany, Greece, Israel, Oman, Qatar, Saudi Arabia, Spain, Turkey, United Arab Emirates, United Kingdom, Vietnam
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Ruxolitinib as GVHD Prophylaxis in AA Patients

The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C] Labelled BIA 5-1058

Cardiovascular Diseases

United Kingdom
Tanta University

Not yet recruiting

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

Non Alcoholic Steatohepatitis

Egypt
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
National University of Malaysia

Unknown

Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

Diabetes Mellitus | Chronic Kidney Diseases | Diabetic Retinopathy

Malaysia
Jadran Galenski laboratorij d.d.

Completed

Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL

Primary Open Angle Glaucoma of Both Eyes

Russian Federation
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE)

Type 2 Diabetes Mellitus

United States, Italy, Spain, Sweden, Canada, Bulgaria, Poland, Czechia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Solid Tumor

China
Boehringer Ingelheim

Terminated

Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

Crohn Disease
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
Janssen Research & Development, LLC

Completed

A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants

Healthy

Belgium
Teva Pharmaceuticals USA

Completed

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

Healthy

United States
University Health Network, Toronto

Recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK)

Kidney Transplant Recipients

Canada
Center for Outcomes Research and Clinical Epidemiology...
Italian Society of Diabetology

Not yet recruiting

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial (GOLDEN-AGE)

Diabetes Mellitus, Type 2
H. Lundbeck A/S

Completed

Bioequivalence Study of Lu AF35700

Healthy

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) (CONSCIOUS-1)

Aneurysmal Subarachnoid Hemorrhage

United States, Canada
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany

Search clinical trials for: 5 mg empagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations